Patients with Multiple Myeloma at Risk for Second Primary Malignancies

With the development of improved treatment methods, patients with multiple myeloma (MM) are experiencing improved survival and the incidence of secondary primary malignancies in this group of patients is not well described.

Data from 30,630 patients who were 1-year survivors of MM in the Surveillance, Epidemiology, and End Results (SEER) program was analyzed by Cutshall and colleagues.

Incidence of hematologic malignancies was significantly increased in these patients, more so than incidence of solid tumors, which was also somewhat increased. The incidence of leukemia was noted to decrease over the three time periods studied, while the incidence of lymphoma was noted to increase.